Roche snaps up gene tech firm in $272M deal

Madison, WI-based Nimblegen Systems, a gene chip maker, has been scooped up by Roche for $272.5 million. The University of Wisconsin spin-off had been planning an IPO which it had filed for last March. The company's technology uses high density DNA microarrays to illuminate drug targets and gives Roche a bigger presence in the DNA sequencing field.

"This acquisition represents a further milestone in our strategy to strengthen our position as a major player and complete solution provider in the genomics research market," Severin Schwan, the head of Roche's diagnostics unit, said in a statement.

- read the report from The Capital Times

Related Articles:
ASCO: Roche to swiftly expand cancer portfolio. Report
Roche snares 454's sequencing tech in buyout. Report
Roche shakes up R&D, eyes new buyouts. Report
Roche to boost R&D spend, reorganize research. Report

Suggested Articles

Monte Rosa Therapeutics raised $96 million to ramp up its pipeline of "molecular glue"

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

The reported requirements suggest a company is unlikely to have the data needed to support an EUA before the election in six weeks.